Simtuzumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| type = mab

| image =

| alt =

| mab_type = mab

| source = zu

| target = LOXL2

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 1318075-13-6

| ATC_prefix = none

| ATC_suffix =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 11Z5AIU653

| PubChem =

| IUPHAR_ligand = 8412

| DrugBank =

| ChemSpiderID = none

| C=6558 | H=10134 | N=1736 | O=2037 | S=50

}}

Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis.[http://www.ama-assn.org/resources/doc/usan/simtuzumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab], American Medical Association. It binds to LOXL2 and acts as an immunomodulator.{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url =https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf }} In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. {{cite web | title = Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis | date = 5 January 2016 | publisher = Gilead | url = http://www.gilead.com/news/press-releases/2016/1/gilead-terminates-phase-2-study-of-simtuzumab-in-patients-with-idiopathic-pulmonary-fibrosis}}